ALPS Medical Breakthroughs ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
ALPS Medical Breakthroughs ETF SBIO
- NAV / 1-Day Return 56.22 / −2.45 %
- Total Assets 197.1M
-
Adj. Expense Ratio
0.500%
- Expense Ratio 0.500%
- Distribution Fee Level —
- Share Class Type ETF
- Category Health
- Investment Style Small Blend
- Min. Initial Investment —
- Status Open
- TTM Yield 0.00
- Turnover 58%
USD | NAV as of Oct 06, 2026 | 1-Day Return as of Oct 06, 2026, 12:20 AM GMT+0
Morningstar’s Analysis SBIO
Will SBIO outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 31.0
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
CG Oncology Inc | 3.88 | 8M | Healthcare |
Oruka Therapeutics Inc | 3.64 | 7M | Healthcare |
Travere Therapeutics Inc Ordinary Shares | 3.49 | 7M | Healthcare |
Definium Therapeutics Inc Ordinary Shares | 3.27 | 6M | Healthcare |
Dianthus Therapeutics Inc | 3.21 | 6M | Healthcare |
Veradermics Inc | 3.17 | 6M | Healthcare |
Edgewise Therapeutics Inc | 2.92 | 6M | Healthcare |
Relay Therapeutics Inc Ordinary Shares | 2.70 | 5M | Healthcare |
Xenon Pharmaceuticals Inc | 2.39 | 5M | Healthcare |
IDEAYA Biosciences Inc | 2.34 | 5M | Healthcare |